HOUSE 1829117th CongressReferred to the Subcommittee on Health.
Pharmacy Benefit Manager Accountability Study Act of 2021
- Last Action
- 3/12/2021
Actions
- 2021-03-12Referred to the Subcommittee on Health.
- 2021-03-11Referred to the House Committee on Energy and Commerce.
- 2021-03-11Introduced in House
- 2021-03-11Introduced in House
CRS Summary
As of 2021-03-11 (00)
Pharmacy Benefit Manager Accountability Study Act of 2021
This bill requires the Government Accountability Office to report on the role of pharmacy benefit managers in the pharmaceutical supply chain and recommend legislative actions to lower the cost of prescription drugs. The report must address the use of rebates and fees, the average prior authorization approval time, and the use of step therapy within the 10 largest pharmacy benefit managers.
Cosponsors (20)
- Earl Carter (R-GA)
- Jefferson Van Drew (R-NJ)
- Jerry Carl (R-AL)
- Fred Keller (R-PA)
- H. Griffith (R-VA)
- Bill Posey (R-FL)
- Cynthia Axne (D-IA)
- Peter Welch (D-VT)
- Victoria Spartz (R-IN)
- Michael Guest (R-MS)
- Gregory Murphy (R-NC)
- Mariannette Miller-Meeks (R-IA)
- Matthew Rosendale (R-MT)
- STEVE CHABOT (R-OH)
- Steve Cohen (D-TN)
- Glenn Grothman (R-WI)
- Glenn Thompson (R-PA)
- Scott Perry (R-PA)
- Mary Miller (R-IL)
- Ralph Norman (R-SC)
Subjects
- Congressional oversight
- Drug therapy
- Government employee pay, benefits, personnel management
- Government studies and investigations
- Health care costs and insurance
- Inflation and prices
- Medicaid
- Medicare
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.